Runben Biotechnology (SH:603193) Huaxin Securities·2025-10-22 11:25Investment Rating - The report assigns a "Buy" investment rating for the company, marking its first coverage [10]. Core Insights - The company reported a total revenue of 1.238 billion yuan for the first three quarters of 2025, representing a 19% year-on-year increase, while the net profit attributable to shareholders was 266 million yuan, up 2% year-on-year [5]. - The company's mosquito repellent products achieved a significant revenue increase of 49% in Q3 2025, driven by heightened demand due to dengue fever incidents [9]. - Despite stable revenue growth, increased sales and management expenses have pressured profit margins, leading to a net profit margin decrease of 5 percentage points to 22.93% in Q3 2025 [7]. Revenue and Profit Analysis - For Q3 2025, total revenue reached 342 million yuan, a 17% increase year-on-year, while net profit decreased by 3% to 79 million yuan [5][7]. - The company's gross margin improved by 1 percentage point to 58.96%, but the sales expense ratio increased by 6 percentage points to 29.09% due to heightened sales resource investment and rising e-commerce channel costs [7]. Product Performance - The mosquito repellent segment saw a revenue increase to 132 million yuan in Q3 2025, with sales volume rising by 32% to approximately 21.55 million units [9]. - Conversely, revenue from baby care products decreased by 3% to 146 million yuan, and essential oil products saw a 7% decline in revenue to 43 million yuan [9]. Market Position and Future Outlook - The company has established a strong market presence in the home and personal care sector, with significant market shares in its three core product lines: mosquito repellent, baby care, and essential oils [10]. - The report forecasts earnings per share (EPS) of 0.77, 0.93, and 1.16 yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (PE) ratios of 35, 29, and 23 times [10].